Graft-versus-host disease (GVHD) remains a major challenge for progress in allogeneic
hematopoietic cell transplantation. Steroids continue to be the most effective firstline therapy …

Graft-versus-host disease (GVHD) is the primary cause of non-relapse-related morbidity and
mortality in patients who undergo hematopoietic stem cell transplantation. Dermatologic …

Background aims: Corticosteroids are the standard first-line treatment for acute graft-versus-
host disease (aGVHD), but they are associated with many complications, and less than half …

Chronic graft-versus-host disease (cGVHD) affects 30–50% of hematopoietic stem cell
transplant (HSCT) patients with skin involvement in about 70%. Among sclerodermiform …

A 43-year-old woman who had undergone allogeneic bone marrow transplant for chronic
myeloid leukemia developed chronic GVHD. Despite cyclosporine A and low-dose …

Extracorporeal photochemotherapy (EP) is a therapeutic approach to the treatment of drug-
resistant graft-vs.-host disease (GVHD) that uses the known immunosuppressive and …

Extracorporeal exposure of peripheral blood mononuclear cells to the photosensitizing
compound 8-methoxypsoralen and ultraviolet A radiation has been shown to be effective in …

Extracorporeal exposure of peripheral blood mononuclear cells to the photosensitizing
agent 8-methoxypsoralen and UV-A radiation has been shown to be effective in the …

Acute graft-versus-host disease (aGVHD) is a major complication of allogeneic
hematopoietic cell transplantation (HCT). In 1966, Billingham defined three criteria for the …

Graft versus host disease (GvHD) occurs in half the patients who receive allogenic
haematopoietic stem cell transplantation and is a major contributor for the morbidity and …